As a part of our research for novel potent and orally available acyl-CoA: cholesterol acyltransferase (ACAT) inhibitors that can be used as anti-atherosclerotic agents, we recently reported the discovery of the (4-phenylcoumarine)acetanilide derivative 1. However, compound 1 showed adrenal toxicity in animal models. In order to search for safer ACAT inhibitors that do not have adrenal toxicity, we examined the inhibitory activity of ACAT in human macrophage and adrenal cells. The introduction of a carboxylic acid moiety on the pendant phenyl ring and the adjustment of the lipophilicity led to the discovery of (2E) 
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Atherosclerosis is one of the risk factors for stroke and coronary heart diseases. The progression of atherosclerotic lesions is associated with the accumulation of cholesteryl esters in macrophage-derived foam cells of the arterial wall. 1) Acyl-CoA: cholesterol acyltransferase (ACAT) is an intracellular enzyme that catalyzes the intracellular cholesterol esterification. Two ACAT isozymes have been identified to date. ACAT-1 is expressed ubiquitously in various human tissues and cells, such as various types of macrophages, adrenal glands, sebaceous glands, liver, and intestine. [2] [3] [4] [5] ACAT-2 is expressed exclusively in the small intestine and liver. [2] [3] [4] [5] The progression of atherosclerotic lesions is associated with the accumulation of cholesteryl esters through ACAT-1 in macrophage foam cells of the arterial wall. [5] [6] [7] Approaches that target arterial plaques with ACAT inhibitors have been investigated experimentally for two decades. 8) ACAT inhibitors interfere with intracellular cholesterol transport within plaque macrophages and may delay the formation of foam cells while activating reverse cholesterol transport. Experimental evidence suggested that ACAT inhibitors reduced and stabilized atherosclerotic plaques in animals. [9] [10] [11] In addition, we have previously reported that the (4-phenylcoumarin)acetanilide derivative 1 is a potent ACAT inhibitor, which showed potent regressive effects on atherosclerotic plaques in apolipoprotein E (apoE)-knockout mice 12) (Table 1 ). However, compound 1 and its related compounds showed potent adrenal toxicity in guinea pigs (data not shown).
Although the adrenal toxicity was probably caused by the acute increase in free cholesterol levels in adrenal cells, the relationship between ACAT inhibition and adrenal toxicity has not been fully clarified. [13] [14] [15] Recently, Takahashi et al. reported that pactimibe showed less potent ACAT inhibitory activity in adrenal tissue than in other tissues 16) (Fig. 1 ). While the cause was not discussed in the paper, we speculated that it is possible to find compounds possessing a similar profile by using cell-based assays and that such compounds may show reduced adrenal toxicity. By the screening of our compound collection around compound 1, compound 2 was found to show moderate selectivity for macrophages over adrenal cells in ACAT inhibition (Table 1) . The common feature of both 2 and pactimibe seems to be the carboxylic acid moiety, and we therefore hypothesized that this acidic moiety could lead to the identification of selective compounds. In this paper, we report a modification of the carboxylic acid moiety of compound 2 in order to improve Discovery of a Novel Acyl-CoA: Cholesterol Acyltransferase Inhibitor: The Synthesis, Biological Evaluation, and Reduced Adrenal Toxicity of (4-Phenylcoumarin)acetanilide Derivatives with a Carboxylic Acid Moiety a) Enzymatic ACAT inhibitory activity was determined by using homogenates from human THP-1 macrophages. b) Cellar ACAT inhibitory activity in human macrophage and adrenal was determined by using THP-1 and H295R cell-lines, respectively. c) Selectivity was evaluated by the value of IC 50 (adrenal)/IC 50 (macrophage). Fig. 1 . Structure of Pactimibe the potency and the selectivity for macrophages in cell-based assays. The adrenal toxicity of the optimized compounds was also evaluated.
Chemistry (4-Phenylcoumarin)acetanilide derivatives were synthesized by the construction of the coumarin skeleton according to our previous report (Chart 1) 12) and the successive introduction of a carboxylic acid moiety (Charts 2-6). 2-Hydroxybenzophenone 4, which was prepared from anisole 3 and 3-bromobenzoyl chloride by Friedel-Crafts acylation, was converted into coumarinacetate 5 by 1,8-diazabicyclo [5.4 .0]undec-7-ene (DBU)-mediated condensation with ethyl 4-chloro-4-oxobutanoate and cyclization in onepot synthesis. The ester 5 was hydrolyzed under acidic conditions to give acetic acid 6. Aldehyde 7 was prepared by another method. Anisole 3 was transformed into phenol 8 by bromination and demethylation. Treatment of compound 8 with n-butyl lithium generated a dilithiated compound, which reacted with 3-(1,3-dioxolan-2-yl)benzaldehyde, followed by oxidation with manganese(IV) dioxide to afford 2-hydroxybenzophenone 9. Construction of the coumarin ring was performed by the typical method to give coumarinacetate 10. Hydrolysis of both the ester group and the 1,3-dioxolan group under acidic conditions resulted in coumarinacetic acid 7. The acids 6 and 7 was converted into acyl chloride, and the corresponding acyl chloride was coupled with anilines 11 to afford coumarinacetanilides 12 and 13a, b.
The aldehydes 13a and b were oxidized to give corresponding acids 2 and 14 as shown in Chart 2. The bromide 6 was converted into propenoate 15 or its b-methyl analog 17 by the Heck reaction with ethyl acrylate or methyl crotonate (Chart 3). The propenoate 15 was transformed into propionate 16 by hydrogenation with Raney Ni. The aldehyde 13a was reacted with triethyl 4-phosphonopropionate and triethyl 2-phosphonocrotonate to give diene 18 and a-methyl analog 20 (Chart 4). The diene 18 was converted into pentanoate 19 by hydrogenation. These esters 15-20 were hydrolyzed to give the corresponding acids 21b, d, and e-h (Chart 5). Acetic acid 21a and butyric acid 21c were synthesized by the Erundt-ainstert reaction as a key step (Chart 6).
17) The acids 14 and 21b were converted into acyl chloride, and the corresponding acyl chloride was reacted with diazomethane, which was followed by treatment with methanol and silver(II) oxide to afford methyl ester analogs 22 and 23, respectively. Hydrolysis of the esters 22 and 23 afforded corresponding acids 21a and c.
Results and Discussion
In Vitro Study The synthesized compounds were examined for ACAT inhibitory activities in three ways (Table 2) . We determined the enzymatic activity by using the human macrophage homogenates derived from the THP-1 cell line and the cellular activities by using both of the human macrophage and adrenal cell lines, THP-1 and H295R, respectively. The selectivity for macrophages over adrenal cells was evaluated by the ratio of each IC 50 value (IC 50 (adrenal)/IC 50 (macrophage)).
First, we replaced the chlorine at the 4-position on the anilide moiety of compound 2 with a fluorine in order to improve its activity on the basis of our previous structure-activities relationship study.
12) Compound 14 showed more potent inhibitory activity than compound 2 with respect to enzymatic activity, as we expected, and its selectivity for macrophage was slightly improved compared with compound 2.
Thus, a further modification of the carboxylic acid moiety was examined with compound 14 in order to improve the potency and the selectivity for macrophages in cell-based assays. Compound 21a showed a weaker enzymatic activity than compound 14. Compound 21c was the most potent ACAT inhibitor among the synthesized compounds.
Compounds 21b-h showed similar potent inhibitory activities in macrophage cells despite possessing different enzymatic activities. On the other hand, the more lipophilic compounds, 21c and d, showed more potent ACAT inhibitory activities in adrenal cells than the other compounds. These results show that the ACAT inhibitory activity might be more susceptible to lipophilicity in adrenal cells than in macrophage cells. The enhancement of adrenal ACAT inhibition led to a lower selectivity for macrophages. Compounds 21b and e with log D values ranging from 2.8 to 3.1 showed potent inhibitory activities to ACAT in macrophages and high selectivity for macrophages over adrenal cells (26-, 28-fold, respectively). The selectivity was determined by a balance between the effects of the carboxyl acid moiety and the lipophilicity.
As a result of the in vitro studies, we chose compounds 21b and e as candidates for further investigation in order to confirm the reduced adrenal toxicity properties. Compound 1 was also tested as a reference compound of potent adrenal toxicity.
Adrenal Toxicological Test in Guinea Pig Adrenal toxicity was evaluated by a histopathologic examination in adrenal cortex 24 h after the intravenous administration of compounds 1, 21b and e in order to remove differences in their bioavailability (Table 3) . Compound 1 showed adrenal toxic-Reagents and conditions: (a) triethyl 4-phosphonocrotonate, NaH, THF, 0°C to rt, 0.5 h; (b) Raney Ni, H 2 , EtOH, rt, overnigh; (c) triethyl 2-phosphonopropionate, NaH, THF, 0°C to rt 0.5 h.
Chart 4
ity at a dose of 5 mg/kg. This toxicity was characterized by adrenal cortical necrosis. Compound 21b showed no evidence of toxicity at a dose of 15 mg/kg and moderate necrosis in only one of three cases at a dose of 50 mg/kg. Surprisingly, compound 21e showed no adrenal toxicity even at a high dose of 50 mg/kg. Thus, compound 21e may show high adrenal safety in sufficient plasma drug levels that are far in excess of the concentration necessary to inhibit ACAT in the walls of blood vessels.
Ex Vivo Study in Atherosclerotic Rabbit
In order to predict the anti-atherosclerotic effects in a short period, the ACAT activities in walls of blood vessels were measured after daily oral administration of compounds 1 and 21e for 3 d (Table 4) . Both compounds 1 and 21e showed similar ACAT inhibitory activities at a dose of 1 and 10 mg/kg, respectively.
Conclusion
We investigated a (4-phenylcoumarin)acetanilide series in an effort to identify ACAT inhibitors with reduced adrenal toxicity. We hypothesized that the carboxylic acid moiety may lead to the identification of selective compounds and a) Enzymatic ACAT inhibitory activity was determined by using homogenates from human THP-1 macrophages. b) Cellar ACAT inhibitory activity in human macrophage and adrenal was determined by using THP-1 and H295R cell lines, respectively. c) Selectivity was evaluated by the value of IC 50 (adrenal)/IC 50 (macrophage). d) LogD values were measured at pH 6.8. 
21e NT --a) Compounds in dimethylsulfoxide were intravenously administered in guinea pig (nϭ3). The degree of adrenal toxicity was determined by histological diagnosis; ϩ: evidence of adrenal cortical necrosis. -: no evidence of adrenal cortical necrosis. NT: not tested. b) Modest evidence of adrenal cortical necrosis was observed in one of three case. evaluated the carboxylic acid analogs in cell-based assays with macrophages and adrenal cells. Adjustment of the lipophilicity of the compounds led to the discovery of (2E)-3- [4-(3-Bromophenyl)-7-chloro-6-methyl-2-oxo-2H-chromen-3-yl]acetic Acid (6) To a suspension of 4 (186 g, 571 mmol) in CH 3 CN (400 ml) was added DBU (230 ml, 1530 mmol). A solution of ethyl succinyl chloride (157 g, 954 mmol) was added dropwise to the mixture at 40°C for 1 h. After stirring for 0.5 h, water (450 ml) was added and the precipitate was collected by filteration and washed with EtOH to give crude ethyl [4-(3-bromophenyl)-7-chloro-6-methyl-2-oxo-2H-chromen-3-yl]acetate (5) (182 g). To the crude 5, AcOH (1600 ml) and conc. HCl (600 ml) were added and the mixture was refluxed for 1 h. After concentration of the solvent, the residue was washed with water and dried. The obtained solid was crystallized from EtOAc to give 6 (166 g, 71%) as colorless crystals: mp Ͼ270°C (decomp.); 
2-[4-(3-Bromophenyl)-7-chloro-6-methyl-2-oxo-2H-chromen-3-yl]-N-[4-fluoro-2-(trifluoro-methyl)phenyl]acetamide (12)
To a solution of 6 (42.0 g, 103 mmol) in THF (400 ml) and DMF (5 drops) was added oxalyl chloride (11.0 ml, 124 mmol). The mixture was stirred at room temperature for 0.5 h. After concentration of the solvent, the residue was dissolved with THF (400 ml). To the solution was added 4-fluoro-2-(trifluoromethyl)aniline (11a) (14.7 ml, 120 mmol) and the mixture was stirred at room temperature overnight. The mixture was diluted with water and extracted with EtOAc. The organic layer was separated, washed with 1 N HCl aq., sat. NaHCO 3 aq and water successively, dried over MgSO 4 2-Bromo-5-chloro-4-methylphenol (8) To a solution of 3 (98 g, 62.6 mmol) in AcOH (350 ml) was added dropwise bromine (100 g, 62.6 mmol) dissolved in AcOH (150 ml). After the addition, the mixture was stirred for 1 h. The resulting mixture was treated with Na 2 S 2 O 3 aq., followed by stirring for 1 h. 1H, s) .
(4-Chloro-2-hydroxy-5-methylphenyl)[3-(1,3-dioxolan-2-yl)phenyl] methanone (9) n-Buthyl lithium (1.6 M in hexane, 300 ml, 480 mmol) was added dropwise to a solution of 8 (48.7 g, 220 mmol) in THF (400 ml) at Ϫ78°C. After 0.5 h, a solution of 3-(1,3-dioxolan-2-yl)benzaldehyde (39.2 g, 220 mmol) in THF (100 ml) was added dropwise and the resulting mixture was stirred for 1 h, then allowed to warm to room temperature. The mixture was quenched with sat. NH 4 Cl aq. and extracted with EtOAc. The organic layer was washed with brine, dried over MgSO 4 and concentrated to give the oily product, which was used for the next reaction without further purification. A mixture of this product and MnO 2 (52.2 g, 600 mmol) in toluene (600 ml) was stirred at reflux with a Dean-Stark apparatus to remove water azeotropically. After 4 h, the mixture was filtered through a Celite pad and the filtrate was concentrated. The residue was purified by silica gel column chromatography (hexane-EtOAc) to give 9 (28.3 g, 44%) as an oil: Ethyl {7-Chloro-4-[3-(1,3-dioxolan-2-yl)phenyl]-6-methyl-2-oxo-2H-chromen-3-yl}acetate (10) Ethyl succinyl chloride (12.7 ml, 88.8 mmol) was added dropwise to a solution of 9 (28.3 g, 88.8 mmol) and Et 3 N (12.4 ml, 88.8 mmol) in THF (200 ml) at 0°C, and the mixture was stirred for 0.5 h. After evaporation of the solvent, the residue was partitioned between water and EtOAc. The organic layer was washed with brine dried over MgSO 4 and concentrated. The residue was purified by silica gel column chromatography (hexane-EtOAc) to give a yellow oil (27.4 g, 69%). The obtained product was dissolved in toluene (300 ml), and DBU (4.49 ml, 30.0 mmol) was added. The resulting mixture was stirred under reflux with a Dean-Stark apparatus to remove water azeotropically. After 2 h, the mixture was partitioned between water and EtOAc. The organic layer was washed with brine dried over MgSO 4 86 mmol) in AcOH (150 ml) and conc. HCl (75 ml) was refluxed for 1 h. After concentration of the solvent, the residue was washed with water and dried to give crude [7-chloro-4-(3-formylphenyl)-6-methyl-2-oxo-2H-chromen-3-yl]acetic acid (7) (2.50 g) as a solid, which was used for the next reaction without further purification. The crude 7 was converted into 13a in a manner similar to that described for 12.
Colorless 
